Financials data is unavailable for this security.
View more
Year on year Johnson & Johnson grew revenues 6.46% from 79.99bn to 85.16bn while net income improved 95.94% from 17.94bn to 35.15bn.
| Gross margin | 70.22% |
|---|---|
| Net profit margin | 22.92% |
| Operating margin | 27.19% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in USDView more
In 2023, Johnson & Johnson increased its cash reserves by 54.73%, or 7.73bn. The company earned 22.79bn from its operations for a Cash Flow Margin of 26.76%. In addition the company generated 878.00m cash from investing, though they paid out 15.83bn more in financing than they received.
| Cash flow per share | 7.46 |
|---|---|
| Price/Cash flow per share | 19.23 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in USDView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in USD
Year on year, growth in dividends per share increased 5.62% while earnings per share excluding extraordinary items fell by -15.30%. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 2.61% |
|---|---|
| Div growth rate (5 year) | 5.83% |
| Payout ratio (TTM) | 45.62% |
| EPS growth(5 years) | -1.47 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 79.18 |
More ▼
